“Conventional drugs have only a limited impact on spasticity associated with multiple sclerosis and are rarely satisfactory. A solution for oral transmucosal delivery (spray) containing a mixture of cannabis extracts (2.7 mg of delta-9-tetrahydrocannabinol + 2.5 mg of cannabidiol per spray) has been granted marketing authorisation in France for patients who are inadequately relieved by standard treatments. Three double-blind, placebo-controlled trials in a total of about 300 patients tested this combination, in addition to ongoing treatment, for periods of 6 to 14 weeks. Individually, none of these trials showed any tangible anti-spastic efficacy, but two combined analyses showed “response rates” of about 35% with the mixture versus about 25% with placebo. In a trial with 572 patients, the 241 patients who “responded” after 4 weeks of treatment were randomised to either continue using the cannabis extract or receive placebo. Twelve weeks later, 75% of patients using the extract were still “responders”, versus 51% of patients switched to placebo. The principal adverse effects of the cannabis extracts consist of neuropsychiatric disorders that resolve on treatment withdrawal. The potential for abuse increases with the dose and is tangible from 16 sprays per day. Pharmacokinetic interactions due to P-glycoprotein inhibition are likely. Treatment during pregnancy may lead to neonatal withdrawal symptoms. In practice, about 10% of patients in whom standard anti-spastic medications are unsatisfactory benefit from a specific effect of the cannabis extracts contained in this oral spray.”
Tag Archives: THC
The Pharmacokinetics, Efficacy, Safety, and Ease of Use of a Novel Portable Metered-Dose Cannabis Inhaler in Patients With Chronic Neuropathic Pain: A Phase 1a Study.
“Chronic neuropathic pain is often refractory to standard pharmacological treatments.
Although growing evidence supports the use of inhaled cannabis for neuropathic pain, the lack of standard inhaled dosing plays a major obstacle in cannabis becoming a “main stream” pharmacological treatment for neuropathic pain.
The objective of this study was to explore the pharmacokinetics, safety, tolerability, efficacy, and ease of use of a novel portable thermal-metered-dose inhaler (tMDI) for cannabis in a cohort of eight patients suffering from chronic neuropathic pain and on a stable analgesic regimen including medicinal cannabis…
This trial suggests the potential use of the Syqe Inhaler device as a smokeless delivery system of medicinal cannabis, producing a Δ9-THC pharmacokinetic profile with low interindividual variation of Cmax, achieving pharmaceutical standards for inhaled drugs.”
http://www.ncbi.nlm.nih.gov/pubmed/25118789
http://www.thctotalhealthcare.com/category/neuropathic-pain/
CANNABINOIDS INCREASE LUNG CANCER CELL LYSIS BY LYMPHOKINE-ACTIVATED KILLER CELLS VIA UPREGULATION OF ICAM-1.
“Cannabinoids have been shown to promote the expression of the intercellular adhesion molecule 1 (ICAM-1) on lung cancer cells as part of their anti-invasive and antimetastatic action…
Cannabidiol (CBD), a non-psychoactive cannabinoid, enhanced the susceptibility of cancer cells to adhere to and subsequently lysed by LAK cells, with both effects being reversed by a neutralizing ICAM-1 antibody…
ICAM-1-dependent pro-killing effects were further confirmed for the phytocannabinoid Δ9-tetrahydrocannabinol (THC) and R(+)-methanandamide, a stable endocannabinoid analogue…
Altogether, our data demonstrate cannabinoid-induced upregulation of ICAM-1 on lung cancer cells to be responsible for increased cancer cell susceptibility to LAK cell-mediated cytolysis.
These findings provide proof for a novel antitumorigenic mechanism of cannabinoids.”
Anti-Cancer Effects In Active Component Of Marijuana
“Guillermo Velasco and colleagues, at Complutense University, Spain, have provided evidence that suggests that cannabinoids such as the main active component of marijuana (THC) have anticancer effects on human brain cancer cells.
In the study, THC was found to induce the death of various human brain cancer cell lines and primary cultured human brain cancer cells by a process known as autophagy. Consistent with the in vitro data, administration of THC to mice with human tumors decreased tumor growth and induced the tumor cells to undergo autophagy.
As analysis of tumors from two patients with recurrent glioblastoma multiforme (a highly aggressive brain tumor) receiving intracranial THC administration showed signs of autophagy, the authors suggest that cannabinoid administration may provide a new approach to targeting human cancers.”
http://www.medicalnewstoday.com/releases/144770.php
“Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673842/
Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: A randomized controlled trial.
“There is a great concern about the safety of THC-based drugs in older people (≥65 years), as most of THC-trials did not include such group. In this phase 1, randomized, double-blind, double-dummy, placebo-controlled, cross-over trial, we evaluated the safety and pharmacokinetics of three oral doses of Namisol®, a novel THC in tablet form, in older subjects….
In conclusion, THC appeared to be safe and well tolerated by healthy older individuals. Data on safety and effectiveness of THC in frail older persons are urgently required, as this population could benefit from the therapeutic applications of THC.”
The Potential Therapeutic Effects of THC on Alzheimer’s Disease.
“The purpose of this study was to investigate the potential therapeutic qualities of Δ9-tetrahydrocannabinol (THC) with respect to slowing or halting the hallmark characteristics of Alzheimer’s disease…
These sets of data strongly suggest that THC could be a potential therapeutic treatment option for Alzheimer’s disease through multiple functions and pathways.”
University Of Saskatchewan Research Suggests Marijuana Analogue Stimulates Brain Cell Growth

“A synthetic substance similar to ones found in marijuana stimulates cell growth in regions of the brain associated with anxiety and depression, pointing the way for new treatments for these diseases, according to University of Saskatchewan medical research published today in The Journal of Clinical Investigation.
Xia Zhang, an associate professor in the U of S neuropsychiatry research unit, led the team that tested the effects of HU-210, a potent synthetic cannabinoid similar to a group of compounds found in marijuana. The synthetic version is about 100 times as powerful as THC, the compound responsible for the high experienced by recreational users.
The team found that rats treated with HU-210 on a regular basis showed neurogenesis – the growth of new brain cells in the hippocampus. This region of the brain is associated with learning and memory, as well as anxiety and depression.
The effect is the opposite of most legal and illicit drugs such as alcohol, nicotine, heroin, and cocaine.
“Most ‘drugs of abuse’ suppress neurogenesis,” Zhang says. “Only marijuana promotes neurogenesis.””
http://www.sciencedaily.com/releases/2005/10/051016083817.htm
“Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects… In summary, since adult hippocampal neurogenesis is suppressed following chronic administration of opiates, alcohol, nicotine, and cocaine, the present study suggests that cannabinoids are the only illicit drug that can promote adult hippocampal neurogenesis following chronic administration.” http://www.jci.org/articles/view/25509
Antihistaminic action of (–)-trans-delta 9-tetrahydrocannabinol.

“THC has an antagonistic effect against histamine on the isolated perfused guinea-pig lung and rabbit kidney. This antagonism seems to be a competitive one at the concentrations used and interacts with histamine at H1-receptors. THC also antagonizes the effect of acetylcholine, PGE2, angiotensis II and histamine in the isolated continuously superfused guinea-pig ileum by a non-competitive manner. The antagonism between THC and histamine on the isolated superfused rabbit aortic strips was found to be highly specific, since 100% relaxation was obtained when the muscle contracted by histamine but not by the equipotent doses of angiotensin II and noradrenaline. THC also causes a significant increase in survival time of guinea-pigs when the animals were exposed to histamine aerosol. These results indicate a specific antagonism of THC against histamine in the preparations used in this investigation.”
http://www.ncbi.nlm.nih.gov/pubmed/239651
“antihistaminic /an·ti·his·ta·min·ic/ (-his-tah-min´ik)
|
Tending to neutralize or antagonize the action of histamine or inhibit its production in the body.
n.
An antihistaminic drug.”
|
The endocannabinoid system: a putative role in neurodegenerative diseases.

“Scientific evidence shows that an hypofunction or a dysregulation of the endocannabinoid system may be responsible for some of the symptoms of diseases such as multiple sclerosis, amyotrophic lateral sclerosis, Huntington’s, Parkinson’s and Alzheimer’s diseases.
The aim of this review is to highlight the role of endocannabinoid system in neurodegenerative diseases
Scientific evidence shows that cannabis can provide symptomatic relief in several neurodegenerative diseases such as multiple sclerosis, Huntington’s, Parkinson’s and Alzheimer’s diseases, and amyotrophic lateral sclerosis. These findings imply that a hypofunction or a dysregulation of the endocannabinoid system may be responsible for some of the symptoms of these diseases. Moreover, given the abundance of CB1 receptors in areas associated with movement and executive thought, researchers’ interest has often focused on endocannabinoid levels in patients with motor degenerative disorders.
CONCLUSIONS:
The important role played by endocannabinoid system promises interesting developments, in particular to evaluate the effectiveness of new drugs in both psychiatry and neurology.”
Researchers study neuroprotective properties in cannabis
“With more states opting to legalize the sale of medical marijuana, researchers are taking a closer look at the use of cannabis to treat chronic illnesses.
Dr. Manny Alvarez, senior managing health editor of FoxNews.com, recently sat down with the Medicine Hunter, Chris Kilham, to find out how it’s being studied.
Dr. Manny: Now from the medical marijuana perspective, as far as the treatment of chronic illnesses, what is it about cannabis that makes it that special?
Medicine Hunter: Well, it seems that there are primarily two things – there’s the THC, that’s what people associated with getting high. And that appears to have a saliatory effect on the eyes in case of glaucoma. For people who are suffering from chemotherapy and can’t eat, it helps to get their appetite back. And we also know that it is a potent pain reliever – and science on that goes back to the 1890s.
But there’s another agent in cannabis that is getting more attention now, and that is called cannabidiol. And this is something that you can swallow by the bucket-full, and it won’t get you high at all. But it appears to have profound nerve-protective and brain-enhancing properties. And interestingly enough, it also induces an anti-anxiety effect.
So this appears to be a very important agent, perhaps useful in the treatment of neurodegenerative disorders.
DM: Are they extracting that particular chemical off the marijuana?
MH: There seem to be two pathways that people are taking. You’ve got G.W. pharmaceuticals in Britain that has come out with a whole cannabis fluid spray. You’ve got people also isolating cannabidiol and playing with that in the lab.
I don’t know how this is all going to settle out – I mean, as a whole-plant person, I’m inclined toward the whole extract. But it does appear that this may also have anti-cancer properties, and that’s very intriguing.
DM: Is marijuana addictive?
MH: I would say that people can absolutely become dependent upon it. But not physiologically addictive. And, as you know, that’s not just parsing terms – I mean physiological addiction, you go through very grave withdrawal.
But people can become dependent on it just as they can on any substance.
DM: Tell me about this study in the American Journal of Pediatrics talking about pregnant Jamaican women and the use of pot.
MH: Melanie Dreher, who is the dean of nursing at Rush Medical Center inChicago, did a study in Jamaica. It was actually published in the American Journal of Pediatrics in 1994, but now it’s re-circulating because of all the interest in the neuroprotective properties.
Basically, she studied women during their entire pregnancy, and then studied the babies about a year after birth. And what she studied was a group of women who did smoke cannabis during pregnancy and those who didn’t. She expected to see a difference in the babies as far as birth weight and neuro tests, but there was no difference whatsoever. The differences that the researchers did notice, that are unexplained and kind of curious are that the babies of the women who had smoked cannabis — and we’re talking about daily use during their pregnancy — socialized more quickly, made eye contact more quickly and were easier to engage.
We don’t know why this is so, but all the old saws of smoking during pregnancy will result in low birth weight did not show up — at least in the Jamaican study. In U.S. studies where we’ve seen a similar investigation, women have concurrently been abusing alcohol and other drugs as well.
Alvarez said it’s interesting to note that there may be neuroprotective properties present in cannabis and the cannibidiol extract, but that smoking of any kind in pregnant women is discouraged.”
More research is needed when it comes to medical marijuana, he added.”
http://www.foxnews.com/health/2012/03/20/researchers-study-neuroprotective-properties-in-cannabis/